Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Amylyx Pharmaceuticals discontinued its AMX0035 program for progressive supranuclear palsy after a phase 2b trial failed to show efficacy.

Amylyx Discontinues AMX0035 Program in Supranuclear Palsy Following Disappointing Phase 2b Data

MediciNova's COMBAT-ALS trial reaches full enrollment, exploring ibudilast's potential to treat ALS and improve patient outcomes.

Enrollment Complete for Phase 2b/3 COMBAT-ALS Study of PDE4 Inhibitor Ibudilast

Videos

The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]

Clinical Experience and Considerations With ALS Medication Tofersen: Sandeep Rana, MD

A pivotal phase 3 study explores ampreloxetine's potential to treat neurogenic orthostatic hypotension in multiple system atrophy patients, aiming for FDA approval.

Fully Enrolled CYPRESS Phase 3 Trial to Test Ampreloxetine in Symptomatic Neurogenic Orthostatic Hypotension of MSA

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]

Building Better Pathways for Clinician Educators in Academic Neurology: Tamara Kaplan, MD

The neurologist at Maimonides Medical Center and SUNY Downstate shared how interactive simulations give neurology trainees the chance to practice skills, gain feedback, and move beyond passive learning. [WATCH TIME: 3 minutes]

Clinical and Educational Advantages of Simulations in Training the Next Generation of Neurologists: Nuri Jacoby, MD

, has been with the team since September 2022. Follow her on Twitter 

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.


ATMRD Congress 2025: Top Expert Interviews and Key Takeaways

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Expert Insights on Novel NMOSD Treatments

Treatment Options to Manage and Prevent Relapses in NMOSD

Video content above is prompted by the following:

What treatment options are available for NMOSD (Kümpfel 2024)?

Discuss options available for treatment of the acute phase and relapses and prevention of relapses.

How do the traditional and newer treatments target various aspects of NMOSD pathophysiology?

Three medical experts explore key insights on novel treatments for NMOSD, focusing on relapse management, disability accumulation, and the efficacy of new versus traditional therapies.

This discussion covers the factors leading to relapses and recurring attacks in NMOSD, how disease severity and relapses contribute to disability accumulation, and their impact on patients' quality of life.

Relapses and Disability Accumulation in NMOSD

This discussion examines how disability accumulation may be influenced by the use of less efficacious treatments, compares the efficacy of novel and traditional NMOSD agents in clinical practice, and reviews relapse rates associated with FDA-approved treatments versus off-label and older therapies.

Treatments With Higher Efficacy and Relapses in NMOSD

This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.

Ravulizumab Long-Term Data and Management of NMOSD

Jacqueline Nicholas, MD, MPH, discusses the evolution of NMOSD pathophysiology understanding and the critical role of the complement system in its development.

The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

Jacqueline Nicholas, MD, MPH, discusses available treatment options for NMOSD, including management of acute phases, relapses, and symptom control, as well as how both traditional and newer therapies address different aspects of NMOSD pathophysiology.

Jacqueline Nicholas, MD MPH discusses the importance of targeting NMOSD through different mechanisms of action and highlight key points for communicating with neurologists about the role of the complement system in the disease.

Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.



Complement Inhibitors in NMOSD

Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.


Meningococcal Infection and NMOSD

Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.

Long-term NMOSD Data

Sean Pittock, MD, discusses how he utilizes long-term data in his clinical practice for treating neuromyelitis optica spectrum disorder and offers advice for physicians on incorporating these insights into patient care.

Use of Long-term NMOSD Data in Clinical Practice

 video series brings together pairs of expert clinicians and physicians to independently provide their insights on the latest and most up-to-date clinical care for specific neurologic diseases and disorders.

Treatment Options to Manage and Prevent Relapses in NMOSD

EP: 1.Relapses and Disability Accumulation in NMOSD

EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD

EP: 3.Ravulizumab Long-Term Data and Management of NMOSD

EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System

EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD

EP: 6.Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD

EP: 7.Complement Inhibitors in NMOSD

EP: 8.Meningococcal Infection and NMOSD

EP: 9.Long-term NMOSD Data

EP: 10.Use of Long-term NMOSD Data in Clinical Practice

Newsletter